New Study of Diabetes Drug for COVID-19 Raises Eyebrows

Some question the safety of AstraZeneca's just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19.

from WebMD Health https://ift.tt/2yhv09Y